These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 15999749)

  • 1. [Cardiovascular complications in diabetic dialysis patients].
    Shinozaki M; Hirakata H
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():439-46. PubMed ID: 15999749
    [No Abstract]   [Full Text] [Related]  

  • 2. Parasympathetic neuropathy and LVH.
    Zoccali C
    Nephrol Dial Transplant; 2005 May; 20(5):1011; author reply 1011-2. PubMed ID: 15728266
    [No Abstract]   [Full Text] [Related]  

  • 3. The reno-cardiovascular connection in the patient with Diabetes mellitus: What's new?
    Palau V; Riera M; Soler MJ
    Endocrinol Diabetes Nutr; 2017 May; 64(5):237-240. PubMed ID: 28495318
    [No Abstract]   [Full Text] [Related]  

  • 4. [Therapeutic possibilities in patients with terminal kidney insufficiency as a sequela to diabetic nephropathy].
    Jansen JL
    Ned Tijdschr Geneeskd; 1979 Jan; 123(4):117-24. PubMed ID: 368661
    [No Abstract]   [Full Text] [Related]  

  • 5. Peritoneal dialysis for patients with diabetes and end-stage renal disease: sorting out the biases?
    Finkelstein FO; Smith JD
    ASAIO J; 1996; 42(1):1-3. PubMed ID: 8808447
    [No Abstract]   [Full Text] [Related]  

  • 6. Association between cardiovascular autonomic neuropathy and left ventricular hypertrophy in diabetic haemodialysis patients.
    Nishimura M; Hashimoto T; Kobayashi H; Fukuda T; Okino K; Yamamoto N; Nakamura N; Yoshikawa T; Takahashi H; Ono T
    Nephrol Dial Transplant; 2004 Oct; 19(10):2532-8. PubMed ID: 15252162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can advanced glycation end product inhibitors modulate more than one pathway to enhance renoprotection in diabetes?
    Coughlan MT; Cooper ME; Forbes JM
    Ann N Y Acad Sci; 2005 Jun; 1043():750-8. PubMed ID: 16037302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accumulation of advanced glycation end products and chronic complications in ESRD treated by dialysis.
    Meerwaldt R; Zeebregts CJ; Navis G; Hillebrands JL; Lefrandt JD; Smit AJ
    Am J Kidney Dis; 2009 Jan; 53(1):138-50. PubMed ID: 19036487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Control of arterial pressure in diabetic nephropathy].
    Luño J; García de Vinuesa S
    Nefrologia; 2001; 21(3):240-5. PubMed ID: 11471304
    [No Abstract]   [Full Text] [Related]  

  • 10. Renal and stroke protection in hypertensive patients at CV risk.
    Cardiovasc J Afr; 2007; 18(5):337, 340. PubMed ID: 17985036
    [No Abstract]   [Full Text] [Related]  

  • 11. Diabetic nephropathy: where hemodynamics meets metabolism.
    Forbes JM; Fukami K; Cooper ME
    Exp Clin Endocrinol Diabetes; 2007 Feb; 115(2):69-84. PubMed ID: 17318765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetics on dialysis in Italy: a nationwide epidemiological study.
    Panzetta G; Basile C; Santoro A; Ancarani E; Costantini S; Guarnieri F; Verzetti G
    Nephrol Dial Transplant; 2008 Dec; 23(12):3988-95. PubMed ID: 18658176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology.
    Wolf G
    Eur J Clin Invest; 2004 Dec; 34(12):785-96. PubMed ID: 15606719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic contributions of carbonyl stress and megsin in diabetic nephropathy.
    Inagi R; Nangaku M; Miyata T
    Ann N Y Acad Sci; 2005 Jun; 1043():605-8. PubMed ID: 16037283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxidative stress and advanced glycation in diabetic nephropathy.
    Coughlan MT; Mibus AL; Forbes JM
    Ann N Y Acad Sci; 2008 Apr; 1126():190-3. PubMed ID: 18448815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy.
    Shimoike T; Inoguchi T; Umeda F; Nawata H; Kawano K; Ochi H
    Metabolism; 2000 Aug; 49(8):1030-5. PubMed ID: 10954022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review on pathophysiology and treatment of diabetic kidney disease.
    Satirapoj B
    J Med Assoc Thai; 2010 Nov; 93 Suppl 6():S228-41. PubMed ID: 21280541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diabetes mellitus and cardiovascular risk].
    Valdés F; Lorenzo D; Calviño X; Cao M; Fernández Rivera C; Pérez Fontán M
    Nefrologia; 2001; 21 Suppl 3():52-7. PubMed ID: 11642208
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibition of renin angiotensin system decreases renal protein oxidative damage in diabetic rats.
    Portero-Otín M; Pamplona R; Boada J; Jové M; Gonzalo H; Buleon M; Linz W; Schäfer S; Tack I; Girolami JP
    Biochem Biophys Res Commun; 2008 Apr; 368(3):528-35. PubMed ID: 18243127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Slowing progression along the renal disease continuum.
    Kopyt NP
    J Am Osteopath Assoc; 2005 Apr; 105(4):207-15. PubMed ID: 15928338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.